How to treat hypertension in patients with peripheral artery disease

被引：0
作者：
Denis L. Clement
Marc L. Debuyzere
机构：
[1] Ghent University Hospital,Department of the Dean
来源：
Current Hypertension Reports | 2007年 / 9卷
关键词：
Clopidogrel; Calcium Antagonist; Peripheral Arterial Disease; Felodipine; Peripheral Artery Disease;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The risk of peripheral artery disease is underestimated by many physicians; such risk is further augmented by the presence of hypertension. Detection of these conditions is essential to prevent cardiovascular accidents. This review deals with the management of peripheral artery disease as a risk factor, highlighting the need for triple therapy (antiplatelet drugs, angiotensin-converting enzyme inhibitors, and statins). Treatment of hypertension is approached by reviewing the essentials of the different antihypertensive drugs available, focusing on their peripheral circulatory effect. However, because individual antihypertensive drugs seem not to differ largely in this respect, attention is drawn to the message that the most important task in these patients is to control total cardiovascular risk rather than focusing on the choice of the individual antihypertensive drug.
引用
收藏
页码：190 / 195
页数：5
相关论文
共 79 条
[1]  
Norgren L.(2007)Inter-society Consensus for the management of Peripheral Artery Disease (TASCII) J Vasc Surg 45 S5-S67
[2]  
Hiatt W.R.(2006)ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease Circulation 113 e463-654
[3]  
Dormandy J.A.(2000)A clinical approach to the management of the patient with coronary (Co) and/or carotid (Ca) artery disease who presents with leg ischaemia (Lis) Int Angiol 19 97-125
[4]  
Hirsch A.T.(2005)Temporal trends in the incidence of intermittent claudication from 1950 to 1999 Am J Epidemiol 162 430-437
[5]  
Haskal Z.J.(2000)Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC) J Vasc Surg 31 S1-S296
[6]  
Hertzer N.R.(2006)Cardioprotective medication is associated with improved survival in patients with peripheral arterial disease J Am Coll Cardiol 47 1182-1187
[7]  
Clement D.L.(1992)Mortality over a period of 10 years in patients with peripheral arterial disease N Engl J Med 326 381-386
[8]  
Boccalon H.(1992)Vascular event rates in patients with atherosclerotic cerebrovascular disease Arch Neurol 49 857-863
[9]  
Dormandy J.(2001)Peripheral arterial disease detection, awareness, and treatment in primary care JAMA 286 1317-1324
[10]  
Murabito J.M.(2003)Critical issues in peripheral arterial disease detection and management: a call to action Arch Intern Med 163 884-892
12345678